SCHEMBL17859031

SCHEMBL17859031

Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=N[C@@H](CC(=O)NCCCCCCCCNC(=O)COc1cccc3c1C(=O)N(C1CCC(=O)NC1=O)C3=O)c1nnc(C)n1-2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 20/20 1.00
DDB1 Q16531 19/20 1.00
BRD4 O60885 14/20 1.00
TRIM24 O15164 1/20 1.00
TRIM33 Q9UPN9 1/20 1.00
BRD3 Q15059 1/20 0.99
BRDT Q58F21 1/20 0.99
BET1 O15155 1/20 0.88

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23789740 1.00 CRBN (1.00) CRBNDDB1BRD4TRIM24TRIM33
SCHEMBL17859001 1.00 CRBN (1.00) CRBNDDB1BRD4TRIM24TRIM33
SCHEMBL19556879 0.99 CRBN (1.00) CRBNDDB1BRD4TRIM24TRIM33
SCHEMBL17859034 0.99 CRBN (1.00) CRBNDDB1BRD4TRIM24TRIM33
SCHEMBL30146573 0.99 CRBN (1.00) CRBNDDB1BRD4TRIM24TRIM33
SCHEMBL17553399 0.99 CRBN (1.00) CRBNDDB1BRD4TRIM24TRIM33
SCHEMBL19556839 0.99 CRBN (1.00) CRBNDDB1BRD4TRIM24TRIM33
SCHEMBL19556892 0.99 CRBN (1.00) CRBNDDB1BRD4TRIM24TRIM33
SCHEMBL19556887 0.99 CRBN (1.00) CRBNDDB1BRD4TRIM24TRIM33
SCHEMBL29566239 0.99 CRBN (1.00) CRBNDDB1BRD4TRIM24TRIM33

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025059442-A1 MODULATING PLANT RESPONSES TO STRESS AND GROWTH WITH CHEMICALS REMOTE EPIGENETICS INC. (US) 2025-03-20 WO claimed
WO-2025029640-A1 TARGETING LIPOSOME FOR PROTEIN DEGRADER DELIVERY SIGMA-ALDRICH CO. LLC (US) 2025-02-06 WO claimed
WO-2024229271-A1 NANOPARTICLE-BASED THERANOSTIC PLATFORM FOR DIAGNOSIS AND TREATMENT OF SENESCENCE-RELATED PATHOLOGIES MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2024-11-07 WO claimed
CN-118512610-A Novel carrier PROTACs lipid ultrasonic microbubbles and preparation method and application thereof 重庆医科大学附属第二医院 2024-08-20 CN claimed
WO-2024152648-A1 USE OF BET PROTEIN DEGRADATION AGENT IN PREVENTION AND TREATMENT OF DISEASES RELATED TO RETINAL DEGENERATIVE CHANGE 中山大学中山眼科中心 2024-07-25 WO claimed
CN-117695219-A X-ray radiation responsive proteolytic targeting chimeric nano micelle and preparation method and application thereof 中国药科大学 2024-03-15 CN claimed
EP-4314018-A1 METHODS AND COMPOSITIONS FOR HIGH-POTENCY POLYPEPTIDE-BASED PROTEIN INHIBITION Baylor College of Medicine (US) 2024-02-07 EP claimed
US-20230355711-A1 VIMENTIN AND FRAGMENTS OR DERIVATIVES THEREOF FOR CORONAVIRUS TREATMENT AND PREVENTION THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 2023-11-09 US claimed
CN-116585322-B Use of BET protein degradation agent in preventing and treating diseases related to retinal degenerative changes 中山大学中山眼科中心 2023-10-13 CN claimed
EP-4243805-A1 COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION Gbiotech S.À.R.L. (CH) 2023-09-20 EP claimed
US-20230210902-A1 SARS-COV-2-SPECIFIC T CELLS NATIONAL INSTITUTES OF HEALTH 2023-07-06 US claimed
EP-4149496-A1 SARS-COV-2-SPECIFIC T CELLS Board of Regents, The University of Texas System (US) 2023-03-22 EP claimed
US-20220401553-A1 PARAPOXVIRUS FOR CONDITIONING FOR AND TREATMENT OF CORONAVIRUS INFECTIONS AICURIS GMBH & CO. KG (DE) 2022-12-22 US claimed
WO-2022213076-A1 METHODS AND COMPOSITIONS FOR HIGH-POTENCY POLYPEPTIDE-BASED PROTEIN INHIBITION BAYLOR COLLEGE OF MEDICINE (US) 2022-10-06 WO claimed
US-20220288051-A1 METHODS FOR TREATING CANCER USING SERIAL ADMINISTRATION OF E3 UBIQUITIN LIGASE DEGRADERS DANA-FARBER CANCER INSTITUTE, INC. 2022-09-15 US claimed
EP-3906970-B1 PARAPOXVIRUS FOR CONDITIONING AND TREATMENT OF CORONAVIRUS INFECTIONS AICURIS GMBH & CO KG (DE) 2022-07-06 EP claimed
US-20220193204-A1 USES OF A2 DOMAIN OF VON WILLEBRAND FACTOR BAYLOR COLLEGE OF MEDICINE (US) 2022-06-23 US claimed
EP-4010081-A1 COMBINATION THERAPY FOR TREATMENT OF CANCER Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (US) 2022-06-15 EP claimed
EP-3969036-A1 USES OF A2 DOMAIN OF VON WILLEBRAND FACTOR Baylor College of Medicine (US) 2022-03-23 EP claimed
WO-2022029334-A1 COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION GBIOTECH S.À.R.L. (CH) 2022-02-10 WO claimed